357 research outputs found
Faces and Places in Fashion: Meg Flather, Home Shopping Diva
No full textMeg Flather has spent decades building a multi-faceted career in performance, cosmetics and media. As author of Lessons, Lyrics and Lipstick, Meg performs entertaining and inspirational seminars for men and women embarking on similar vocations. As national makeup artist for OLAY, Meg worked closely with public relations, marketing and product development. As a home shopping brand ambassador, Meg has grown sales for PERLIER on TSC, Canada, Aloette on Shop NBC, PRAI on TVSN, Australia, StriVectin on QVC, and TSC, Canada. In December, 2015, Meg became the New York based Director of Education for TATCHA skincare.Meg began her cosmetic career in New York City. She was special events captain for all metropolitan accounts for Clinique, resident make-up artist for Yves St. Laurent at Bergdorf Goodman, held the highest national sales record for both Stila and Body and Soul at Barney’s, and raised customer service and artistry standards at all Face Stockholm locations. As an expert in her field, Meg has been featured on The Discovery Channel, in 15 national publications and her artistry credits include People Magazine, NBC Daytime, CNN, 20/20, The View, documentary films and numerous private clients.Part presentation, part Q&A, the "Faces & Places in Fashion" lecture series is an opportunity to connect students and the public alike to the pulse of the fashion industry in an open and conversational setting
Economic evaluation of complete revascularization for patients with multivessel disease undergoing primary percutaneous coronary intervention
No full textObjective: To determine the cost-effectiveness of complete revascularisation at index admission compared to infarct-related artery (IRA) treatment only, in patients with multi-vessel disease undergoing Primary percutaneous coronary intervention (P-PCI) for ST-segment elevation Myocardial Infarction (STEMI). Methods: Economic evaluation of a multi-centre randomised trial comparing complete revascularisation at index admission to IRA-only P-PCI in patients with multi-vessel disease (12 month follow-up). Overall hospital costs (costs for P-PCI procedure(s), hospital stay and any subsequent readmissions) were estimated. Outcomes were major adverse cardiac events (MACE, a composite of all-cause death, recurrent myocardial infarction, heart failure, and ischemia-driven revascularisation) and quality-adjusted life years (QALYs) derived from the EQ-5D-3L. Multiple imputation was undertaken. The mean incremental cost and effects, with associated 95% confidence intervals (95%CI), the incremental cost-effectiveness ratio (ICER) and the cost-effectiveness acceptability curve (CEAC) were estimated. Results: Based on 296 patients, the mean incremental overall hospital cost for complete revascularisation was estimated to be –£215.96 (–£1,390.20 to £958.29), compared to IRA-only, with a per-patient mean reduction in MACE events of 0.170 (0.044 to 0.296) and a QALY gain of 0.011 (-0.019 to 0.041). According to the CEAC, the probability of complete revascularisation being cost-effective was estimated to be 72.0% at willingness to pay of £20,000 per QALY. Conclusions: Complete revascularisation at index admission was estimated to be more effective (in terms of MACE and QALYs) and cost-effective (overall costs were estimated to be lower and complete revascularisation thereby dominated IRA-only). There was, however, some uncertainty associated with this decision
Long-term cost-effectiveness analysis of nebivolol compared with standard care in elderly patients with heart failure: an individual patient-based simulation model
No full textBackground and objective: The SENIORS trial demonstrated that nebivolol is effective in the treatment of heart failure in elderly patients (e.g. =70 years). This analysis evaluates the cost effectiveness of nebivolol compared with standard treatment. Methods: An individual patient-simulation model based on a Markov modelling framework was developed to compare costs and outcomes for nebivolol and standard care in patients with heart failure starting treatment at the age of 70 years. Health states were defined by New York Heart Association (NYHA) class and death. At a given NYHA class and a given cycle, patients could die, be hospitalized for cardiovascular disease or remain stable. Risks for these events were derived from individual patient data from the SENIORS trial. The risk of each event in a given cycle was based on the subject's baseline characteristics and time in the current health state. The economic analysis was conducted from the UK NHS perspective with a lifetime horizon. The costs (€; year 2006 values) considered were drug costs for nebivolol and other cardiac drugs, costs of GP visits, outpatient specialist visits and cardiovascular-related hospitalizations. Univariate and probabilistic sensitivity analysis was conducted. Results: In the baseline analysis, the total cost per patient was €6740 and €9288, and QALYs were 5.194 and 5.843 for patients aged 70 years at the start of treatment for the standard treatment and nebivolol groups, respectively. The probabilistic sensitivity analysis provided an incremental cost-effectiveness ratio of €3926 (95% CI 3731, 4159) per QALY. Conclusions: This analysis indicates that nebivolol appears to be a cost-effective treatment for elderly patients with heart failure compared with standard care
Is liraglutide associated with myocardial protection in ST-elevation myocardial infarction?
No full textPost-operative atrial fibrillation and long-term risk of stroke after isolated coronary artery bypass graft surgery
No full textBackground: Post-operative atrial fibrillation (pAF) following coronary artery bypass grafting (CABG) is a common complication. Whether pAF is associated with an increased risk of cerebrovascular accident (CVA) remains uncertain. We investigated the association between pAF and long-term risk of CVA by performing a post-hoc analysis of 10-year outcomes of the Arterial Revascularization Trial (ART). Methods: For the present analysis, among patients enrolled in the ART (n=3102), we excluded those who did not undergo surgery (n=25), had a prior history of atrial fibrillation (n=45), or had no information regarding the incidence of pAF (n=9). The final population consisted of 3023 patients of whom 734 (24.3%) developed pAF with the remaining 2289 maintaining sinus rhythm (SR). Competing risk and Cox regression analysis were used to investigate the association between pAF and the risk of CVA. Results: At 10 years, the cumulative incidence of CVA was 6.3% (4.6-8.1) vs 3.7% (2.9-4.5) in patients with pAF and SR respectively. pAF was an independent predictor of CVA at 10 years (HR 1.53; 95%CI 1.06-2.23; P-value=0.025) even when CVAs that occurred during the index admission were excluded from the analysis (HR 1.47; 95% 1.02-2.11; P=0.04). Conclusions: Patients with pAF after CABG are at higher risk of CVA. These findings challenge the notion that pAF is a benign complication
ACP Journal Club. CABG added no benefit to medical therapy for preventing death in CAD with heart failure
No full text
- …
